Choice of Antihypertensive agent According to Stage of Hypertension
|
Overview
The present study in the Journal of the associations of Physicians of India (JAPI) intended to estimate the comorbidities and risk factors among patients with hypertension in India. The study evaluated the current practice of hypertension management and the choice of therapy based on hypertension grade, risk factors, and comorbidities.
The study used Electronic medical record data of Indian adult hypertensive patients) who had two blood pressure readings.
A total of 1,00,075 patients, were included in the study. The proportion of patients with a BMI of less than 25 was 8.1%, 25-29.9 was 11.9%, and greater than 30 Kg/m2 was 8.8%. The mean BP of patients with hypertension was: grade, grade II, and grade III.
Mean low-density lipoprotein, serum creatinine, and mean HbA1c levels were highest among patients with grade III hypertension. Commonly observed comorbidities were type 2 diabetes mellitus, dyslipidemia, and chronic kidney disease. Top concomitant medications included anti-diabetic therapies, drugs for dyslipidemia, and anti-platelet therapies.
Researchers, therefore, concluded that the most prescribed Anti Hypertensive Drug monotherapies were angiotensin receptor II blockers (ARBs) and calcium channel blockers (CCBs) and the most prescribed combination therapies were angiotensin receptor II blockers + diuretics and angiotensin receptor II blockers + calcium channel blockers. Telmisartan and amlodipine+telmisartan for patients with comorbid Type 2 Diabetes Mellitus or dyslipidemia and metoprolol for those with coronary artery disease were the commonly prescribed Anti Hypertensive Drugs.
Reference: Md.Yunus Khan, Sucheta Pandit, Jamshed Dalal "Retrospective, Observational Study to Determine the Choice of Antihypertensive agent According to Stage of Hypertension, Risk factors and Co-morbidities in Real World Setting in India: A Report of Baseline Data", volume issue: 69; JAPI.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
